201.56
price up icon0.84%   +1.68
pre-market  Pre-market:  201.56  
loading
Laboratory Corp. Of America Holdings stock is currently priced at $201.56, with a 24-hour trading volume of 590.05K. It has seen a +0.84% increased in the last 24 hours and a -4.29% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $198.4 pivot point. If it approaches the $201.6 resistance level, significant changes may occur.
Previous Close:
$199.88
Open:
$198.66
24h Volume:
590.05K
Market Cap:
$16.99B
Revenue:
$12.30B
Net Income/Loss:
$433.10M
P/E Ratio:
26.95
EPS:
7.48
Net Cash Flow:
$667.50M
1W Performance:
+2.88%
1M Performance:
-4.29%
6M Performance:
-8.17%
1Y Performance:
-13.96%
1D Range:
Value
$198.07
$201.68
52W Range:
Value
$191.97
$243.30

Laboratory Corp. Of America Holdings Stock (LH) Company Profile

Name
Name
Laboratory Corp. Of America Holdings
Name
Phone
336-229-1127
Name
Address
358 South Main Street, Burlington, NC
Name
Employee
60,000
Name
Twitter
@labcorp
Name
Next Earnings Date
2024-06-13
Name
Latest SEC Filings
Name
LH's Discussions on Twitter

Laboratory Corp. Of America Holdings Stock (LH) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-09-24 Initiated Evercore ISI In-line
Jan-03-24 Initiated Barclays Equal Weight
Sep-06-23 Initiated HSBC Securities Hold
Dec-12-22 Downgrade Citigroup Buy → Neutral
Sep-19-22 Downgrade Argus Buy → Hold
Aug-22-22 Resumed Morgan Stanley Overweight
Jan-28-22 Downgrade Deutsche Bank Buy → Hold
Jan-11-21 Upgrade Argus Hold → Buy
Jan-11-21 Downgrade Wolfe Research Peer Perform → Underperform
Jan-08-21 Downgrade Wolfe Research Outperform → Peer Perform
Jul-14-20 Upgrade BofA Securities Neutral → Buy
Jul-13-20 Upgrade Wolfe Research Peer Perform → Outperform
Jun-02-20 Resumed Deutsche Bank Buy
May-15-20 Upgrade Mizuho Neutral → Buy
Apr-29-20 Downgrade KeyBanc Capital Markets Overweight → Sector Weight
Apr-27-20 Upgrade Citigroup Neutral → Buy
Apr-27-20 Upgrade Wolfe Research Underperform → Peer Perform
Jan-08-20 Initiated Wells Fargo Overweight
Jul-16-19 Upgrade BofA/Merrill Underperform → Neutral
Jun-21-19 Upgrade Deutsche Bank Hold → Buy
Apr-02-19 Upgrade Jefferies Hold → Buy
Jan-17-19 Initiated UBS Buy
Jan-03-19 Downgrade BofA/Merrill Neutral → Underperform
Dec-03-18 Downgrade Craig Hallum Buy → Hold
Oct-30-18 Downgrade Argus Buy → Hold
Oct-25-18 Downgrade Canaccord Genuity Buy → Hold
Oct-19-18 Resumed BofA/Merrill Buy
Jun-07-18 Upgrade KeyBanc Capital Mkts Sector Weight → Overweight
May-01-18 Upgrade Robert W. Baird Neutral → Outperform
Mar-23-18 Initiated Argus Buy
View All

Laboratory Corp. Of America Holdings Stock (LH) Financials Data

Laboratory Corp. Of America Holdings (LH) Revenue 2024

LH reported a revenue (TTM) of $12.30 billion for the quarter ending March 31, 2024, a +4.62% rise year-over-year.
loading

Laboratory Corp. Of America Holdings (LH) Net Income 2024

LH net income (TTM) was $433.10 million for the quarter ending March 31, 2024, a -56.71% decrease year-over-year.
loading

Laboratory Corp. Of America Holdings (LH) Cash Flow 2024

LH recorded a free cash flow (TTM) of $667.50 million for the quarter ending March 31, 2024, a -49.84% decrease year-over-year.
loading

Laboratory Corp. Of America Holdings (LH) Earnings per Share 2024

LH earnings per share (TTM) was $4.95 for the quarter ending March 31, 2024, a -55.08% decline year-over-year.
loading
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates through two segments, LabCorp Diagnostics and Covance Drug Development. It offers a range of clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C, prostate-specific antigen, tests for sexually-transmitted diseases, hepatitis C tests, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests that are used by hospitals, physicians and other healthcare providers and commercial clients to assist in the diagnosis, monitoring and treatment of diseases and medical conditions through the examination of substances in blood, tissues, and other specimens. The company also provides specialty testing services in the areas of women's health, allergy, diagnostic genetics, cardiovascular disease, infectious disease, endocrinology, oncology, coagulation, pharmacogenetics, toxicology, medical drug monitoring, and pain management; and esoteric testing, cancer diagnostics, and other complex procedures. In addition, it provides drug development solutions and laboratory testing services; and testing services through a sales force to the managed care organizations, biopharmaceutical companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, food and nutritional companies, and independent clinical laboratories. The company has collaboration with university, hospital and academic institutions, such as Boston University, Columbia University, Duke University, Johns Hopkins University, The Mount Sinai Hospital, the University of Tennessee, and Yale University to license and commercialize new diagnostic tests, as well as with Baptist Health. The company was founded in 1971 and is headquartered in Burlington, North Carolina.
$109.07
price up icon 0.38%
diagnostics_research WAT
$294.25
price down icon 0.23%
$316.39
price up icon 0.98%
diagnostics_research MTD
$1,447.76
price down icon 0.48%
diagnostics_research A
$131.83
price up icon 1.52%
Cap:     |  Volume (24h):